Tag

Compounding

All articles tagged with #compounding

health-policy23 days ago•4 min saved

FDA Panel Backs Six Peptides for Compounding, But Legal Access Hangs on Rulemaking

An FDA Pharmacy Compounding Advisory Committee narrowly recommended six of seven peptides for inclusion on the 503A Bulks List—BPC-157, KPV, TB-500, MOTS-c, Semax, and Epitalon—with emideltide rejected. The vote advances a nonbinding advisory step, but none of the substances is FDA-approved and final access hinges on proposed and final rulemaking. Available studies are short and small, leaving safety and efficacy data weak. The panel's reconstitution drew scrutiny over conflicts of interest, and payers should expect continued out-of-pocket use and online sourcing, with emphasis on careful medication reconciliation and safety monitoring until more data are available.

via ajmc.com|

#503a #compounding #fda

health1 month ago•17 min saved

FDA Panel Clears 6 of 7 Banned Peptides for Compounding, Sparking Safety Debate

An FDA Pharmacy Compounding Advisory Committee voted to remove six peptides from the Category 2 ban list (BPC-157, KPV, TB-500, MOTs-C, epitalon, semax) while keeping emideltide restricted, signaling broader access to unapproved peptides via compounding despite limited safety and efficacy data; the non-binding recommendations come amid RFK Jr.’s push to expand peptide use, raising questions about real-world safety and effectiveness.

via Gizmodo|

#compounding #fda #health

health-policy1 month ago•8 min saved

Kennedy pushes peptide access as FDA panel weighs compounding route

An FDA advisory panel appointed by Health Secretary RFK Jr. recommended allowing licensed compounding pharmacies to produce several peptides with prescriptions, signaling a shift away from the FDA’s caution over safety and efficacy. Supporters argue it would curb a thriving unregulated market and expand patient access via providers, while critics warn it could bypass formal FDA review and safety safeguards. The final decision remains with the FDA, though Kennedy has authority to overrule agency conclusions, potentially reshaping the peptide market and care options.

via Politico|

#compounding #fda #health-policy

health1 month ago•5 min saved

FDA panel nudges peptide rules closer to clinics despite scientific uncertainty

An FDA advisory panel narrowly voted to loosen restrictions on four peptides (BPC-157, KPV, TB-500, MOTS-c), recommending they be added to the list of compounds that compounding pharmacies may produce, even as agency scientists warned about a lack of evidence and unclear chemical identities; the final decision will come from an FDA rule proposal, with votes showing notable dissent and ongoing safety and data concerns.

via NBC News|

#compounding #fda #health

health1 month ago•9 min saved

FDA panel weighs allowing compounding of experimental peptides amid safety concerns

An FDA advisory committee will review seven experimental peptides to decide if they should be added to the 503A Bulks List, potentially letting state-licensed compounding pharmacies prepare them with prescriptions. Regulators say there is insufficient evidence on safety and effectiveness, raising concerns about long-term risks, while advocates argue a regulated pathway could reduce unsafe online sourcing. The decision is advisory, with final regulatory choices falling to the agency and potentially reshaping access to these non-FDA-approved peptides.

via CNN|

#503a #compounding #fda

personal-finance1 month ago•20 min saved

Dividend Growth Outpaces High-Yield for Long-Term Retirement Income

The article argues that a dividend-growth approach (starting with about 3.5% yield and payouts growing around 7% annually) can surpass a fixed 10% high-yield strategy over time because compounding and inflation protection boost long-term income. It presents three yield paths—Conservative (3–4%), Moderate (5–7%), and Aggressive (8–14%)—to reach a target of $80,000 annual retirement income, showing how growth-oriented dividend stocks (e.g., Johnson & Johnson, Procter & Gamble, Coca‑Cola, Microsoft, Lowe’s, Texas Instruments) can compound to roughly $310,000 in 20 years versus a flat 10% yield that would still be $80,000 in 20 years if payouts don’t grow. The piece cautions that high-yield vehicles like BDCs and mortgage REITs should be treated as spendable capital with principal risk managed accordingly, and emphasizes matching income needs to growth potential rather than chasing the highest starting yield.

via 24/7 Wall St.|

#compounding #dividend-growth #high-yield

business1 month ago•21 min saved

Trump Accounts promise big returns, but experts urge caution on long-term projections

Trump Accounts offer a newborn seed and up to $5,000-per-year contributions with the aim of turning a child’s savings into a sizable sum, but four financial planners say the flashy projections assume long-term stock-market gains that are unlikely to persist. Using conservative 7% returns, maxed contributions could total about $1 million by age 45 (roughly $185,000 by 18), with time and compounding doing most of the work. Key caveats include tax treatment (tax-deferred, taxed as ordinary income on withdrawal), the risk of a child controlling the account at 18, and the need to treat the Trump Account as an addition to—not a replacement for—other vehicles like 401(k)s and 529 plans. Some advisers even suggest converting to a Roth IRA later. Employers’ contributions can help, but the bottom line remains: this is a useful tool with significant caveats, not a guaranteed path to wealth.

via Yahoo Finance|

#business #compounding #education-savings

personal-finance2 months ago•23 min saved

Patience Pays: Turning $500K Into a Six-Figure Dividend Income

Turning $500,000 into a six-figure inflation‑adjusted dividend income isn’t about chasing the highest yield. It’s about blending modest, durable yields with steady dividend growth to compound over 20–30 years. The piece lays out three paths: a conservative 3.5% yield with 7% annual growth (e.g., Johnson & Johnson, Procter & Gamble) could reach about $130k by year 30; a 5% yield portfolio (Realty Income) offers earlier cash but slower compounding; and a high-yield, durability‑conscious 10% yield (AGNC) carries greater risk to principal. It emphasizes total returns, tax considerations, reinvesting dividends, and patience to grow income over time.

via 24/7 Wall St.|

#compounding #dividend-growth #johnson-and-johnson

health4 months ago•5 min saved

FDA to Review Easing Peptide Restrictions as RFK Jr. Endorses Them

The FDA will convene an advisory panel in July to decide whether seven popular injectable peptides should be added to the list allowing pharmacies to compound them, signaling a potential loosening of restrictions on unapproved therapies championed by RFK Jr. While supporters say it could improve access, critics warn of safety risks and the lack of extensive human testing; any change would still require formal rulemaking, and the process may be influenced by Kennedy’s public stance and current agency vacancies.

via CBS News|

#compounding #fda #health

business6 months ago•4 min saved

Novo Nordisk targets Hims with lawsuit over cheap Wegovy copycats

Novo Nordisk filed a lawsuit seeking a permanent ban and damages against Hims & Hers for allegedly selling compounded, patent-infringing versions of Wegovy (semaglutide); Hims paused its obesity-pill copycat after regulatory scrutiny as FDA actions loom, underscoring a broader crackdown on compounded GLP-1 drugs used by as many as 1.5 million Americans amid intense obesity-drug competition.

via CNBC|

#business #compounding #hims-and-hers

business7 months ago•20 min saved

Lilly and Novo Accused of Blocking Telehealth to Suppress Cheaper GLP-1 Versions

A lawsuit filed by Strive Specialties alleges Eli Lilly and Novo Nordisk blocked telehealth partners to curb compounded GLP-1 therapies, potentially impacting about 1.5 million U.S. patients who rely on cheaper, personalized versions of Wegovy/Ozempic. The plaintiffs say these agreements limit prescriber choice and patient access, while the drugmakers argue the deals target mass-produced copies. Novo Nordisk has highlighted the past Hims & Hers partnership ended after compounded Wegovy issues, and Lilly labeled the suit a bid to divert attention from Strive’s own conduct. The case underscores ongoing tensions between compounded vs. branded GLP-1 drugs, access, and pricing in the weight‑loss market.

via Sherwood News|

#business #compounding #eli-lilly

business10 months ago•4 min saved

Warren Buffett's ETF Suggestion Could Turn $300 Monthly into $1 Million

Warren Buffett recommends investing in the Vanguard S&P 500 ETF as a low-cost, diversified way to benefit from the long-term growth of American companies, suggesting that a monthly $300 investment could grow to $1 million over 35 years through the power of compounding.

via The Motley Fool|

#business #compounding #etf

business1 year ago•1 min saved

Hims & Hers CEO defies Novo Nordisk amid weight-loss drug market turmoil

Hims & Hers Health plans to continue making cheaper, compounded versions of Novo Nordisk's weight-loss drug Wegovy despite Novo ending their partnership and accusing the company of legal violations. The CEO emphasized their commitment to patient choice and independence from pharmaceutical pressure, even as legal and regulatory challenges persist.

via Seeking Alpha|

#business #compounding #hims-and-hers

finance1 year ago•4 min saved

Maximize Your Savings with Top CD Rates and Strategies Today

Investing $5,000 in a 6-month certificate of deposit (CD) can lock in current interest rates, which are influenced by the Federal Reserve's rate decisions. With rates currently declining, locking in a CD rate can be beneficial. Interest on CDs is compounded monthly, enhancing earnings over time. For example, at a 4.43% rate, a $5,000 investment could earn approximately $111.77 in six months. CDs offer a secure, passive income option, but it's important to understand terms and potential penalties for early withdrawal.

via AOL|

#cds #compounding #finance

finance2 years ago•7 min saved

"Beware: Buffett's Warning on How Smart People Go Broke Through Dividend Investing"

Warren Buffett warns against the dangers of leverage, cautioning that it can lead even the smartest investors to financial ruin. This applies to dividend investing as well, as excessive reliance on debt can undermine the stability and growth of a company's dividend. Prudent balance sheet management is crucial for dividend investors, and examples of companies with attractive yields and strong balance sheets include Enterprise Products Partners, Realty Income, and Brookfield Infrastructure. Smart investors should prioritize slow and steady compounding over the allure of quick gains through leverage, as the long-term rewards of value investing and dividend compounding are substantial and attainable.

via Seeking Alpha|

#balance-sheet-management #compounding #dividend-investing